Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Maziarz, Richard T., Waller, Edmund K., Jaeger, Ulrich, Fleury, Isabelle, McGuirk, Joseph, Holte, Harald, Jaglowski, Samantha, Schuster, Stephen J., Bishop, Michael R., Westin, Jason R., Mielke, Stephan, Teshima, Takanori, Bachanova, Veronika, Foley, Stephen R., Borchmann, Peter, Salles, Gilles A., Zhang, Jie, Tiwari, Ranjan, Pacaud, Lida B., Ma, Qiufei, Tam, Constantine S.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Immunobiology and Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042998/
https://ncbi.nlm.nih.gov/pubmed/32074277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001026
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars